Multiple Sclerosis Information
View Article  First Electronic Injection Device for MS
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the launch of the innovative individually adjustable electronic injection device RebiSmart(TM) for the self-administration of Rebif(R) (interferon beta-1a), the company's disease-modifying   more »
View Article  Continuous Disease-Modifying Treatment = Better Outcomes in MS
Patients with multiple sclerosis (MS) who adhere to their treatment with interferon (IFN) beta-1a without interruption have lower relapse and progression rates than patients who do not adhere to their medication as regularly   more »